echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Olaparib maintenance treatment for advanced ovarian cancer followed up to 7 years of overall survival prognosis

    J Clin Oncol: Olaparib maintenance treatment for advanced ovarian cancer followed up to 7 years of overall survival prognosis

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In the SOLO1/GOG 3004 trial, maintenance therapy with the poly (ADP-ribose) polymerase inhibitor olaparib provides a sustained progression-free survival benefit


    In this double-blind, phase 3 clinical trial, newly diagnosed patients with advanced ovarian cancer who responded to platinum-based chemotherapy with BRCA mutations were randomly assigned to the olaparib group (n=260) or placebo group (n=131) for maintenance for up to 2 years



    As of July 2022, 149 of the 391 patients have died


    At year 7, 67.


    Taken together, the findings suggest that in newly diagnosed patients with advanced ovarian cancer with BRCA mutations, olaparib maintenance therapy improves overall survival prognosis and has clinical significance, although there is no statistical significance according to predetermined criteria; Support these patients with olaparib maintenance therapy for long-term remission


    Original Source:

    Paul DiSilvestro, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.